Your browser is no longer supported. Please, upgrade your browser.
Settings
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-6.14 Insider Own0.10% Shs Outstand395.95M Perf Week-2.69%
Market Cap94.51B Forward P/E13.99 EPS next Y17.07 Insider Trans- Shs Float395.29M Perf Month1.00%
Income-2422.60M PEG- EPS next Q3.64 Inst Own87.50% Short Float1.68% Perf Quarter9.75%
Sales15.37B P/S6.15 EPS this Y23.00% Inst Trans-2.58% Short Ratio2.16 Perf Half Y-12.74%
Book/sh181.28 P/B1.32 EPS next Y21.82% ROA3.00% Target Price299.06 Perf Year-14.46%
Cash/sh1.28 P/C186.55 EPS next 5Y13.49% ROE5.70% 52W Range195.50 - 322.68 Perf YTD-23.62%
Dividend- P/FCF21.43 EPS past 5Y-50.40% ROI-1.30% 52W High-26.03% Beta0.80
Dividend %- Quick Ratio0.90 Sales past 5Y33.40% Gross Margin78.70% 52W Low22.09% ATR5.18
Employees31200 Current Ratio1.00 Sales Q/Q1.50% Oper. Margin-16.50% RSI (14)43.29 Volatility2.14% 2.01%
OptionableYes Debt/Eq0.56 EPS Q/Q9.70% Profit Margin27.00% Rel Volume0.81 Prev Close243.94
ShortableYes LT Debt/Eq0.52 EarningsNov 03 BMO Payout0.00% Avg Volume3.07M Price238.68
Recom1.90 SMA20-0.59% SMA50-3.08% SMA200-7.53% Volume2,500,464 Change-2.16%
Aug-19-16Upgrade Mizuho Neutral → Buy $248 → $318
Aug-09-16Reiterated RBC Capital Mkts Outperform $307 → $300
Aug-09-16Reiterated Deutsche Bank Buy $282 → $278
Aug-05-16Reiterated Mizuho Neutral $232 → $246
Jul-27-16Reiterated Leerink Partners Outperform $272 → $294
Jul-25-16Initiated Credit Suisse Outperform $327
May-13-16Reiterated Mizuho Neutral $250 → $232
Apr-18-16Resumed Goldman Buy $275
Apr-18-16Initiated Guggenheim Neutral
Apr-18-16Downgrade Piper Jaffray Overweight → Neutral $311 → $238
Apr-07-16Resumed Morgan Stanley Overweight $300
Apr-07-16Resumed JP Morgan Overweight
Apr-07-16Reiterated UBS Buy $366 → $300
Apr-07-16Downgrade Susquehanna Positive → Neutral
Apr-06-16Downgrade Mizuho Buy → Neutral $330 → $250
Mar-31-16Reiterated Canaccord Genuity Buy $340 → $320
Feb-23-16Reiterated Mizuho Buy $354 → $330
Feb-23-16Reiterated Deutsche Bank Buy $308 → $339
Feb-19-16Initiated Wells Fargo Outperform
Nov-24-15Reiterated Mizuho Buy $340 → $354
Sep-26-16 04:30PM  Unexpected Twist: Pfizer Scraps Breakup Following Dead Allergen Merger
03:12PM  Drugmaker Pfizer decides not to break up business
12:17PM  Read Scraps Pfizer Break-Up as Megadeals Escape Its Grasp
09:30AM  The Zacks Analyst Blog Highlights: Deutsche Bank, Apple, Therapeutics, Allergan and Gilead Sciences
08:41AM  Allergan Gets FDA Approval for New Line of Breast Implants
06:59AM  Pfizer decides against splitting into two companies at MarketWatch
Sep-23-16 04:28PM  Allergan Announces FDA Approval of NATRELLE INSPIRA® Cohesive Breast Implants PR Newswire
10:22AM  Big trade buys time for gains in Allergan
09:37AM  [$$] US politicians lament inaction over price-gouging drug companies at Financial Times
09:09AM  Allergan/Adamas Launch New Dosage Strengths of Namzaric
08:00AM  Pharma Stock Roundup: Allergan Acquisitions in Focus, J&J to Buy Abbott's AMO
08:00AM  Saluting Biotech M&A: Onward And Upward at Forbes
06:25AM  Allergan's Vitae Buy Could Spark More Interest in Kadmon
Sep-22-16 06:39PM  Traders look for opportunities after Nasdaq hits new all-time high at CNBC
05:00PM  New highs: What's left to buy?
04:35PM  Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle
04:07PM  Will Gilead Make a Good Fit for Allergan? (GILD) at Investopedia
11:20AM  Gilead Sciences (GILD) Stock Lower Despite Bullish Gabelli Note
11:17AM  [$$] Teva, Allergan Pump Up the Pipelines at Barrons.com
10:32AM  Gilead Sciences: A Hidden Asset? at Barrons.com
10:26AM  Allergan is Not Going to Buy Gilead at Bloomberg
08:00AM  Allergan and Adamas Announce U.S. Availability of New Dosage Strengths for NAMZARIC® (Memantine and Donepezil Hydrochlorides) Extended Release for the Treatment of Moderate to Severe Alzheimer's Disease PR Newswire
06:00AM  Jim Cramer's Top Takeaways: Flex, Walt Disney, Allergan
05:53AM  Is Galectin The Next Takeover Target for the Biotech World?
12:39AM  [$$] Big Pharmas Big Checkbooks Drive Biotech Resurgence at The Wall Street Journal
Sep-21-16 07:10PM  Cramer Remix: This tech growth story just got better at CNBC
06:42PM  Allergan CEO says 'the American people deserve to be angry' at price gouging at CNBC
06:25PM  Allergan CEO says 'the American people deserve to be angr...
05:05PM  Allergan's Boldness may not be Limited to Tobira Deal
03:16PM  Biotech: Why NASH is So Hot Right Now at Barrons.com
03:13PM  [$$] Big Pharma's Big Checkbooks Drive Biotech Resurgence at The Wall Street Journal
12:51PM  Moody's: Regulatory, political event risks remain for US drug companies; geographic and product diversity to help mitigate effects at Moody's
11:23AM  Biotech ETFs in Focus on Tobira Therapeutics' Massive Gain
11:04AM  Heres Why Alphabet Inc (GOOG), Vale SA (ADR) (VALE) & Three Other Stocks Are Among Trending Names on Wednesday at Insider Monkey
10:37AM  Gilead Sciences (GILD) Stock Lower, Gabelli: Allergan Could Be Buyer
10:30AM  Allergan Going After Gilead? Gabelli Says CEO 'Playing Chess While The Market Is Playing Checkers'
09:40AM  Allergan Buys 2 Liver Disease-Focused Biopharmas at Investopedia
09:38AM  Gilead Sciences: Allergan's Next Target? at Barrons.com
08:39AM  Biotech Stock Roundup: Tobira Soars on Acquisition Deal, FDA Says Yes to Sarepta DMD Drug
07:21AM  Allergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma
07:10AM  [$$] Allergan to Acquire U.K.'s Akarna Therapeutics at The Wall Street Journal
06:55AM  Allergan Buys NASH Therapy Maker Tobira at Huge Premium
06:53AM  Allergan is paying a stunning 500% premium to buy a clinical-stage biotech at MarketWatch
12:50AM  [$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal at The Wall Street Journal
Sep-20-16 11:06PM  Asian shares mixed as Bank of Japan, Fed mull policy options
09:40PM  [$$] Allergan to Buy Tobira Therapeutics in $1.7 Billion Deal at The Wall Street Journal
06:50PM  Allergan to buy Tobira in push for fatty liver disease drugs
06:45PM  Allergan targets liver disease drugs with Tobira acquisition
06:26PM  Allergan Buys Two Pharmas, CBS Talks Netflix As Market Awaits Fed
06:03PM  Tuesday's top performer: Biotech stocks at CNBC
05:28PM  Allergan Buys Two Liver Disease Companies in Less Than a Day
05:13PM  Why DTS, SolarCity, and Tobira Therapeutics Jumped Today at Motley Fool
04:55PM  How Will Allergan (AGN) Stock React to Akarna Therapeutics Deal?
04:49PM  Why Did Tobira Therapeutics (TBRA) Stock Skyrocket 720% Today?
04:41PM  Allergan pays $50 mln to buy privately-held Akarna Therapeutics at MarketWatch
04:37PM  Allergan just acquired two companies in one day
04:23PM  US STOCKS-Wall St ends flat with Fed, BOJ up next Reuters
04:15PM  Allergan buys second fatty liver-disease company
04:15PM  Allergan Acquires Akarna Therapeutics Adding to its Strong Development Program and Commitment to Innovation in NASH PR Newswire
04:11PM  [$$] Sarepta jumps after drugs regulator boost at Financial Times
04:03PM  Wall Street Creeps Higher Ahead of Fed Decision
04:00PM  STOCKS DO NOTHING AHEAD OF THE FED: Here's what you need to know
03:58PM  Why Tobira Therapeutics Inc Was an Overnight Octuple at Motley Fool
03:28PM  Biotech buyout: The next big liver disease
03:02PM  US STOCKS-Wall St buoyed by healthcare with Fed on deck Reuters
02:54PM  Allergan snares Bay Area drug maker for potential $1.7 billion at bizjournals.com
02:40PM  Stocks Post Modest Gains as Fed Meets, Crude Higher
02:32PM  Ariad Shares Rise Amid Speculation of Potential Buyout at Bloomberg
02:32PM  Ariad Shares Rise Amid Speculation of Buyout Target Potential
02:25PM  Allergan's big premium for Torbira
01:27PM  Allergan: What is It Thinking?!?! at Barrons.com
01:16PM  Allergan Is Making Biotech Expensive Again at Bloomberg
01:06PM  More Squawk from Jim Cramer: Allergan (AGN) Buying Tobira (TBRA) Looks Like 'Such an Overpay'
12:54PM  US STOCKS-Wall St rises on gains in healthcare stocks; Fed eyed
12:25PM  Jim Cramer: Allergan Deal Looks Like an Overpay at TheStreet
12:00PM  Gilead Sciences: Why Allergan's Tobira Purchase is Wonderful, Wonderful News at Barrons.com
11:59AM  Allergan's Chart Is Not Persuasive
11:46AM  Here's Why Conatus Pharmaceuticals (CNAT) Stock Is Soaring Today
11:44AM  This Stock Has Gained Over 700% Today, Plus the Latest on GoPro, Petrobras and Sinclair at Insider Monkey
11:36AM  South S.F. liver disease treatment developer fetches up to $1.7B in sale at bizjournals.com
11:25AM  Tobira Therapeutics Skyrockets on Allergan Acquisition
11:16AM  Stocks Rise as Wall Street Looks to Fed's Decision on Interest Rates
10:32AM  Allergan pays top dollar for 'stepping stones' from neurology to dermatology
10:22AM  Allergan to Buy Tobria in Deal Nearing $1.7 Billion
10:22AM  Allergan to Buy Tobria in Deal Nearing $1.7 Billion at Bloomberg
10:22AM  Tobira Therapeutics (TBRA) Stock Surging After Allergan Deal
09:58AM  US STOCKS-Financials boost Wall St ahead of Fed meet
09:46AM  Allergan (AGN) Stock Down After Tobira Therapeutics Deal
09:05AM  Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen
09:04AM  ALLERGAN PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:53AM  US STOCKS-Wall St set to open higher as investors await Fed meet
08:47AM  Allergan could pay up to an 1,800% premium to acquire a tiny pharmaceutical company
08:42AM  Stock Futures Hold Higher as Housing Starts Slow
08:10AM  Allergan to buy Tobira in deal valued at up to $1.7 billion at MarketWatch
08:00AM  Allergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH PR Newswire
Sep-19-16 03:56PM  Hateful Paper: Washed Out, Worth A Shot at Forbes
11:08AM  Allergan Plc Value Analysis (NYSE:AGN) : September 19, 2016
06:00AM  Trump Means Change Equals Major Inflection Point
Sep-17-16 02:27AM  [$$] Will Bayer's Takeover of Monsanto Be a Bust? at Barrons.com
Sep-16-16 09:19AM  Blog Coverage Allergan Boosts its RandD Expenditure and Pours 639m Dollars in the New Merger
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Brands, US Medical Aesthetics, International Brands, and Anda Distribution segments. The company offers a portfolio of products that provide treatments for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, and medical aesthetics, as well as dermatology and plastic surgery. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. Allergan plc also distributes generic and branded pharmaceutical products primarily to independent pharmacies, pharmacy chains, pharmacy buying groups, and physicians' offices. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.